Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: Carboplatin
Drug: Paclitaxel
Drug: erlotinib hydrochloride

First Posted Date: 2006-02-07

Last Posted Date: 2018-12-06

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 86

Registration Number: NCT00287989

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma

Phase 2

Completed

Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size
Extraocular Extension Melanoma
Iris Melanoma
Recurrent Intraocular Melanoma
Recurrent Melanoma
Stage IV Melanoma

Interventions: Drug: carboplatin
Drug: paclitaxel
Drug: bortezomib

First Posted Date: 2006-02-07

Last Posted Date: 2013-03-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 36

Registration Number: NCT00288041

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Vorinostat, Paclitaxel, and Carboplatin in Treating Patients With Advanced or Refractory Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: vorinostat
Drug: paclitaxel
Drug: carboplatin
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2006-02-07

Last Posted Date: 2013-02-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00287937

Locations: 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States

Combination Chemotherapy and Radiation Therapy in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer

Phase 1

Completed

Conditions: Esophageal Cancer

First Posted Date: 2006-01-25

Last Posted Date: 2013-03-21

Lead Sponsor: Duke University

Target Recruit Count: 13

Registration Number: NCT00281788

Locations: 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States

Combination Chemotherapy With or Without Radiation Therapy in Treating Children With Brain Tumors

Phase 2

Conditions: Brain and Central Nervous System Tumors
Neuroblastoma

First Posted Date: 2006-01-25

Last Posted Date: 2013-09-20

Lead Sponsor: Children's Cancer and Leukaemia Group

Target Recruit Count: 50

Registration Number: NCT00281905

Locations: 🇮🇪
Our Lady's Hospital for Sick Children, Dublin, Ireland
🇬🇧
Birmingham Children's Hospital, Birmingham, England, United Kingdom
🇬🇧
Royal Liverpool Children's Hospital, Alder Hey, Liverpool, England, United Kingdom

and more 17 locations

Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: gemcitabine hydrochloride
Drug: thalidomide
Procedure: conventional surgery

First Posted Date: 2006-01-25

Last Posted Date: 2017-12-28

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 22

Registration Number: NCT00281827

Locations: 🇺🇸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
🇺🇸
Hubert H. Humphrey Cancer Center at North Memorial Outpatient Center, Robbinsdale, Minnesota, United States
🇺🇸
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States

Induction Chemotherapy Using Paclitaxel, Carboplatin, CPT-11 With Pegfilgrastim

Phase 2

Completed

Conditions: Non Small Cell Lung Cancer

First Posted Date: 2006-01-23

Last Posted Date: 2013-02-05

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 24

Registration Number: NCT00280787

Locations: 🇺🇸
University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: docetaxel

First Posted Date: 2006-01-23

Last Posted Date: 2017-07-11

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 75

Registration Number: NCT00280735

Locations: 🇺🇸
University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer

Interventions: Biological: bevacizumab
Drug: carboplatin
Drug: erlotinib hydrochloride
Drug: paclitaxel
Radiation: 3-dimensional conformal radiation therapy

First Posted Date: 2006-01-20

Last Posted Date: 2017-06-19

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 46

Registration Number: NCT00280150

Locations: 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States
🇺🇸
Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
🇺🇸
Batte Cancer Center at Northeast Medical Center, Concord, North Carolina, United States

Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: Erlotinib
Drug: paclitaxel
Procedure: conventional surgery
Radiation: radiation therapy

First Posted Date: 2006-01-18

Last Posted Date: 2020-07-20

Lead Sponsor: Nathan Pennell, MD, PhD

Target Recruit Count: 32

Registration Number: NCT00278148

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy